Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMperator
2024-512635-71-00Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Nonhematologic neoplasms comparing Atezolizumab adjuvant monotherapy with Atezolizumab plus tiragolumab adjuvant combination (2 arms). Primary endpoint: Disease-free survival rate at 24 months. Started Mar 2024; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-512635-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512635-71-00.